NCT06617832Recruiting
Trial Designs for Evaluating Migraine Treatment
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
The study aims to test interactions between drug and placebo-responses in acute migraine treatment and to assess variation in adverse events according to treatment information provided. Using a clinical within-subjects, advanced balanced placebo design, patients with episodic migraine will receive six treatment conditions in a randomized order.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 128 (estimated)
- First submitted
- 20 Sept 2024
- Start date
- 13 Nov 2024
- Primary completion date
- Sept 2028
- Lead sponsor
- University of Aarhus
- Diseases
- Migraine
- NCT number
- NCT06617832
What you commit to
- Study type: Interventional
- Planned participants: 128
- From 13 Nov 2024 to the primary completion date, Sept 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Other concomitant primary headache types except for infrequent tension-type headache
- Use of illegal psychotropic drugs less than a week before participation in the study; regarding cannabis: less than four weeks before participation in the study
Other illness
- Chronic migraine or history of chronic migraine in the last 12 months
- Secondary headache disorders including medication overuse headache
- Severe psychiatric, vascular or liver diseases
- Current substance use disorder
- Cardiac pacemaker or implanted or wearable defibrillator
Lab values
- Current use of preventive migraine treatment (i.e., onabotulinum toxin A, and/or Calcitonin gene-related peptide (CGRP) monoclonal antibodies) (however, stable medical treatment with other migraine prophylactic agents is permitted, e.g. antidepressant, calcium channel blockers, beta blockers and antiepileptic drugs, 4 weeks prior to inclusion until the completion of participation in the study)
Other
- Opioid or barbiturate use in the month preceding screening
- Contraindications or inability to tolerate triptans
- Implanted metallic or electronic device in the head
- Current pregnancy or planned pregnancy (confirmed by pregnancy test and by use of safe contraception as defined by the Danish Medicines Agency) and lactation
Who the study is looking for
- Adults (18-65 years)
- ≥ 1-year history of migraine with or without aura according to the International Classification of Headache Disorders (ICHD-3) diagnostic criteria
- Known episodic migraine (≥ 1 and \< 15 headache days with features of migraine on at least 2-8 days per month for \> 3 months) with and without aura and diagnosed before age 50
- Previous or active use of triptans as acute treatment for migraine
- Ability to speak and read Danish
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dept. of Psychology and Behavioural Sciences Coordinator of this site? Confirm its status | Aarhus C | Denmark | Not yet recruiting |
| Department of Neurology, Aarhus University Hospital Coordinator of this site? Confirm its status | Aarhus N | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.